In a not entirely surprising set of findings, data from a relatively large registry study — to be presented at an upcoming meeting of the American Association of Cancer Research (AACR) — suggest that treatment with abiraterone acetate raises risk for cardiovascular-related mortality among prostate cancer patients with known cardiovascular risk factors. … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, cardiovascular, hospitalizaton, mortality, real world, risk, trials | 4 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 